Meet Evonik at the RNA Leaders Congress in Basel
Join us on March 4-6, 2025 in Basel to learn more about our capabilities for mRNA and gene delivery
We look forward to presenting our broad portfolio of advanced drug delivery solutions, including our plant-derived cholesterol PhytoChol®, our custom lipids portfolio and Evonik's end-to-end CDMO services for lipid nanoparticle (LNP) formulations.
We have served as a global development partner and solutions provider to the pharmaceutical industry for more than 60 years. Our broad portfolio of products, technologies and services is leveraged by more than 1,000 life science customers worldwide, including more than 90 percent of the world’s top pharmaceutical companies, to support the development, scale-up and supply of their APIs, formulations and drug products.
With more than 50 core competencies that extend across chemistry, biotechnology and process engineering, as well as a global network of manufacturing sites and labs, we have the size, strength and versatility to address the specific needs of even the largest or most complex projects.
The following brochures provide an overview of our capabilities in just a few pages.
mRNA and gene delivery
Parenteral Drug Delivery Solutions
Driving the growth of advanced drug delivery
Few, if any, other CDMOs can match our ability to leverage a broad, integrated portfolio of functional excipients, technologies and value-adding services to help design, develop and manufacture pharmaceuticals that are safe, efficacious and differentiated.
We can support you at any stage of the drug development process, including:
- Novel and established functional excipients and superior capabilities for lipids
- Stable supply of plant-derived synthetic cholesterol PhytoChol®
- End-to-end CDMO services for nucleic acid therapeutics
- Seamless support for your formulation and processing needs across all classes of pharmaceuticals, including nucleic acid therapies and other advanced nanomedicines
- Advanced cGMP manufacturing and fill-finish capabilities
The quality of lipids in a lipid nanoparticle assembly is critically important to the functionality of mRNA-based therapeutics. We have identified a key impurity in cationic lipids, N-Oxide, that is responsible for a loss in transcription and translation activity of the mRNA cargo. This study demonstrates that Evonik is capable of manufacturing high-quality lipids with a purity greater than 99% and a consistently low level of the N-Oxide impurity.
Lipid nanoparticle (LNP) formulation development begins on a small scale, often with homemade or benchtop setups, using syringe pumps and easily accessible micro-mixing systems. Once a promising formulation has been identified, the next step is to transition to standardized large-scale impingement mixing systems, such as the high flow T-mixing pumps that were used to produce the COVID-19 vaccines.
But which factors do formulators need to consider when scaling up novel LNP systems? And what hurdles can be expected? This technical note discusses factors such as flow rates, solvent removal, risks when changing equipment and the impact of tangential flow filtration sensitivity. You can learn what needs to be considered to develop a cost- and time-efficient large-scale process.
Get in touch with our experts
We look forward to meeting you, even if you can’t attend the show this time. Simply contact our dedicated colleagues using the links below and we'll arrange a time to discuss your individual project and specific needs.
To learn more about our product and service portfolio, please visit our website or get inspired by some of our articles below.
George William Smith
Senior Business Manager Parenteral Drug Delivery EMEA
Evonik Health Care
Dr. Sophie Hammer
Senior Manager Strategic & Technical Marketing Parenteral Drug Delivery
Evonik Health Care
